Carl P Walther1, Wolfgang C Winkelmayer1, Peter A Richardson2,3, Salim S Virani2,3,4,5, Sankar D Navaneethan1,6,7. 1. Department of Medicine, Section of Nephrology, Baylor College of Medicine, Selzman Institute for Kidney Health, Houston, TX, USA. 2. Health Policy, Quality & Informatics Program, Michael E. DeBakey VA Medical Center Health Services Research & Development Center for Innovations, Houston, TX, USA. 3. Department of Medicine, Section of Health Services Research, Baylor College of Medicine, Houston, TX, USA. 4. Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA. 5. Department of Medicine, Section of Cardiovascular Research, Baylor College of Medicine, Houston, TX, USA. 6. Section of Nephrology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA. 7. Institute of Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA.
Abstract
BACKGROUND: Treatment with renin-angiotensin system inhibitors (RASIs), angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) is the standard of care for those with chronic kidney disease (CKD) and albuminuria. However, ACEI/ARB treatment is often discontinued for various reasons. We investigated the association of ACEI/ARB discontinuation with outcomes among US veterans with non-dialysis-dependent CKD. METHODS: We performed a retrospective cohort study of patients in the Veterans Affairs healthcare system with non-dialysis-dependent CKD who subsequently were started on ACEI/ARB therapy (new user design). Discontinuation events were defined as a gap in ACEI/ARB therapy of ≥14 days and were classified further based on duration (14-30, 31-60, 61-90, 91-180 and >180 days). This was treated as a time-varying risk factor in adjusted Cox proportional hazards models for the outcomes of death and incident end-stage kidney disease (ESKD), which also adjusted for relevant confounders. RESULTS: We identified 141 252 people with CKD and incident ACEI/ARB use who met the inclusion criteria; these were followed for a mean 4.87 years. There were 135 356 discontinuation events, 68 699 deaths and 6152 incident ESKD events. Discontinuation of ACEI/ARB was associated with a higher risk of death [hazard ratio (HR) 2.3, 2.0, 1.99, 1.92 and 1.74 for those discontinued for 14-30, 31-60, 61-90, 91-180 and >180 days, respectively]. Similar associations were noted between ACEI and ARB discontinuation and ESKD (HR 1.64, 1.47, 1.54, 1.65 and 1.59 for those discontinued for 14-30, 31-60, 61-90, 91-180 and >180 days, respectively). CONCLUSIONS: In a cohort of predominantly male veterans with CKD Stages 3 and 4, ACEI/ARB discontinuation was independently associated with an increased risk of subsequent death and ESKD. This may be due to the severity of illness factors that drive the decision to discontinue therapy. Further investigations to determine the causes of discontinuations and to provide an evidence base for discontinuation decisions are needed.
BACKGROUND: Treatment with renin-angiotensin system inhibitors (RASIs), angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) is the standard of care for those with chronic kidney disease (CKD) and albuminuria. However, ACEI/ARB treatment is often discontinued for various reasons. We investigated the association of ACEI/ARB discontinuation with outcomes among US veterans with non-dialysis-dependent CKD. METHODS: We performed a retrospective cohort study of patients in the Veterans Affairs healthcare system with non-dialysis-dependent CKD who subsequently were started on ACEI/ARB therapy (new user design). Discontinuation events were defined as a gap in ACEI/ARB therapy of ≥14 days and were classified further based on duration (14-30, 31-60, 61-90, 91-180 and >180 days). This was treated as a time-varying risk factor in adjusted Cox proportional hazards models for the outcomes of death and incident end-stage kidney disease (ESKD), which also adjusted for relevant confounders. RESULTS: We identified 141 252 people with CKD and incident ACEI/ARB use who met the inclusion criteria; these were followed for a mean 4.87 years. There were 135 356 discontinuation events, 68 699 deaths and 6152 incident ESKD events. Discontinuation of ACEI/ARB was associated with a higher risk of death [hazard ratio (HR) 2.3, 2.0, 1.99, 1.92 and 1.74 for those discontinued for 14-30, 31-60, 61-90, 91-180 and >180 days, respectively]. Similar associations were noted between ACEI and ARB discontinuation and ESKD (HR 1.64, 1.47, 1.54, 1.65 and 1.59 for those discontinued for 14-30, 31-60, 61-90, 91-180 and >180 days, respectively). CONCLUSIONS: In a cohort of predominantly male veterans with CKD Stages 3 and 4, ACEI/ARB discontinuation was independently associated with an increased risk of subsequent death and ESKD. This may be due to the severity of illness factors that drive the decision to discontinue therapy. Further investigations to determine the causes of discontinuations and to provide an evidence base for discontinuation decisions are needed.
Authors: Carl P Walther; Peter A Richardson; Salim S Virani; Wolfgang C Winkelmayer; Sankar D Navaneethan Journal: Nephrol Dial Transplant Date: 2020-02-01 Impact factor: 5.992
Authors: Sandeep Brar; Feng Ye; Matthew T James; Brenda Hemmelgarn; Scott Klarenbach; Neesh Pannu Journal: JAMA Intern Med Date: 2018-12-01 Impact factor: 21.873
Authors: Giuseppe Remuzzi; Piero Ruggenenti; Annalisa Perna; Borislav D Dimitrov; Dick de Zeeuw; Darcy A Hille; Shahnaz Shahinfar; George W Carides; Barry M Brenner Journal: J Am Soc Nephrol Date: 2004-12 Impact factor: 10.121
Authors: Yao Qiao; Jung-Im Shin; Teresa K Chen; Lesley A Inker; Josef Coresh; G Caleb Alexander; John W Jackson; Alex R Chang; Morgan E Grams Journal: JAMA Intern Med Date: 2020-05-01 Impact factor: 21.873
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright Journal: Hypertension Date: 2017-11-13 Impact factor: 9.897
Authors: Sunil Bhandari; Natalie Ives; Elizabeth A Brettell; Marie Valente; Paul Cockwell; Peter S Topham; John G Cleland; Arif Khwaja; Meguid El Nahas Journal: Nephrol Dial Transplant Date: 2015-09-30 Impact factor: 5.992